Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems, PerkinElmer, JPT Peptide, Mt. Sinai, Waters, Nonlinear

Strong MS and Proteomics Spur ABI Revenue Growth in Q4
Applied Biosystems reported a 9 percent increase in revenues for its fiscal fourth quarter with strong business in its mass spectrometry sector and proteomics-related business.
ABI’s mass spectrometry business posted revenues of $134.7 million for the quarter, a 13 percent jump from $118.9 million during the year-ago period.
The company did not break out sales for its proteomics business but in a conference call with Wall Street analysts, Catherine Burzik, ABI president said, “Our proteomics business generated notable results this quarter with significant demand in European markets in our 4800 MALDI TOF/TOf system and Q TRAP products from our customers performing biomarker discoveries and validation.”
For the quarter ended June 30 the company recorded total revenue of $523.1 million, compared to $478.5 million during the year-ago period. Net income was $76.7 million, or $.43ents per basic share, compared to $71.6 million, or $.35 per basic share, for the fourth quarter of fiscal 2005.
Net effect of foreign currency raised earnings per share by approximately 1 cent compared to the year-ago period, the company said.
For fiscal 2006, the company recorded revenue of $1.9 billion, compared to $1.8 billion for fiscal 2005. Net income for the year was $275.1 million, $1.47 per basic share, compared to $236.9 million, $1.21 per basic share, for fiscal 2005.
The company spent $46.3 million on R&D for the quarter. At the end of the quarter Applied Biosystems had $373.9 billion in cash and short-term investments.

PerkinElmer Announces Collaborations, Dividend Payout, and Acquisitions
PerkinElmer has signed two multi-year research collaborations with John Hopkins University and the University of Birmingham, UK to develop biomarker tools and technologies.
David Chan at John Hopkins and Philip Johnson at Birmingham will be working with PerkinElmer’s BioExpression platform for cancer research, the company said.
In a separate collaboration, PerkinElmer will work with the University of Leicester to discover biomarkers that predict preterm birth. PerkinElmer will provide funding, tools and equipment to the effort.
Financial terms were not disclosed for any of the collaborations.
PerkinElmer’s board of directors also declared a quarterly dividend payout of $.07 per share, the company said separately.
The dividend will be payable on Nov. 10 to all stockholders of record as of Oct. 20.
The company completed also its acquisition of JN Macri Technologies, which holds and licenses global patents related to free beta Human Chorionic Gonadotropin, and acquired NTD Laboratories, a reference library specializing in prenatal risk assessment.
The purchase price for the two transactions was about $56.7 million, the company said.

JPT Peptide and Mt.Sinai Collaborate on Food Allergy Biomarkers
JPT Peptide Technologies announced a collaboration with the Mount Sinai School of Medicine to discover B-cell epitopes. MSSM will use JPT’s PepStar peptide-microarray platform to develop vaccines and diagnostics in the field of food allergies.
Financial terms of the agreement were not released.

Waters Receives ISO Certification
The company also announced it had received International Organization for Standardization 13485 certification for its quality management service. ISO 13485 is the international standard specific to medical device development, production, and servicing.

Nonlinear’s Says Its New 2D Software Is Selling Fast
Nonlinear Dynamics’ SameSpots approach has become its fastest selling 2D software, the company announced. Nonlinear is based in Newcastle upon Tyne, UK.
Since launching in March, SameSpots outpaced the sales of Progenesis, an earlier 2D software, during its first 18 months on the market.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.